DDInter387 DDInter1676
Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Cisplatin {u} (Compound) treats {v} (Disease) testicular cancer
Cisplatin {u} (Compound) binds {v} (Gene) SLC31A2
Cisplatin {u} (Compound) is included by {v} (Pharmacologic Class) Platinum-containing Compounds
Cisplatin {u} (Compound) causes {v} (Side Effect) Anaphylactic shock
Cisplatin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lithium carbonate
Cisplatin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Grepafloxacin
Cisplatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Clostridium tetani toxoid antigen (formaldehyde inactivated)
Cisplatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alefacept
Cisplatin {u} may lead to a major life threatening interaction when taken with {v} Iothalamic acid
Cisplatin {u} may lead to a major life threatening interaction when taken with {v} Cladribine
Cisplatin (Compound) treats testicular cancer (Disease)
Cisplatin (Compound) binds SLC31A2 (Gene)
Cisplatin (Compound) is included by Platinum-containing Compounds (Pharmacologic Class)
Cisplatin (Compound) causes Anaphylactic shock (Side Effect)
Cisplatin may cause a minor interaction that can limit clinical effects when taken with Lithium carbonate
Cisplatin may cause a minor interaction that can limit clinical effects when taken with Grepafloxacin
Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated)
Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Alefacept
Cisplatin may lead to a major life threatening interaction when taken with Iothalamic acid
Cisplatin may lead to a major life threatening interaction when taken with Cladribine